Rabeprazole
- Generic Name
- Rabeprazole
- Brand Names
- Aciphex, Pariet
- Drug Type
- Small Molecule
- Chemical Formula
- C18H21N3O3S
- CAS Number
- 117976-89-3
- Unique Ingredient Identifier
- 32828355LL
- Background
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
- Indication
For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
- Associated Conditions
- Duodenal Ulcer, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Heartburn, Helicobacter Pylori Infection, Non-erosive Reflux Esophagitis Disease (NERD), Vomiting, Zollinger-Ellison Syndrome, Develop NSAID-induced gastric ulcers, Erosive reflux esophagitis
- Associated Therapies
- -
PPI-amoxicillin for H. Pylori Treatment
- Conditions
- Interventions
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 732
- Registration Number
- NCT05014685
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2021-06-30
- Last Posted Date
- 2022-05-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT04944771
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Helicobacter Pylori Eradication With Berberine Plus Amoxicillin Triple Therapy Versus Bismuth-containing Quadruple Therapy
- Conditions
- Interventions
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Xijing Hospital of Digestive Diseases
- Target Recruit Count
- 524
- Registration Number
- NCT04697186
- Locations
- 🇨🇳
Xijing Hosipital of Digestive Disease, Xi'an, Shaanxi, China
Bismuth-Metronidazole Triple Therapy for H. Pylori First-line Treatment
- Conditions
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 270
- Registration Number
- NCT04667299
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
A Study to Compare PK, PD and Safety of the AD-214-02 and Rabeprazole
- Conditions
- Interventions
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2021-07-21
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT04622358
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Study of BIIB091 Formulations in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 59
- Registration Number
- NCT04564612
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
A Phase 2 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers.
- Conditions
- Interventions
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2020-08-07
- Lead Sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT04503629
- Locations
- 🇨🇳
The Fisrst Affiliated Hospital of NanChang University, Nanchang, Jiangxi, China
A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants
- First Posted Date
- 2020-07-28
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 35
- Registration Number
- NCT04489797
- Locations
- 🇺🇸
Research Site, Anaheim, California, United States
A Phase 3 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers.
- Conditions
- Interventions
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2020-01-02
- Lead Sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.
- Target Recruit Count
- 448
- Registration Number
- NCT04215653
Relative Bioavailability and PPI Effects of CC-92480 Test and Reference Formulations in Healthy Subjects
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2020-05-08
- Lead Sponsor
- Celgene
- Target Recruit Count
- 24
- Registration Number
- NCT04211545
- Locations
- 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.